Anti-Ro52/TRIM21 seropositivity in interstitial lung disease: effect modification by disease subtype and myositis-specific antibody context
- DOI
- 10.3389/fimmu.2026.1960409
- Published
- 2026-10-16
- Container
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2026.1960409,
title = {Anti-Ro52/TRIM21 seropositivity in interstitial lung disease: effect modification by disease subtype and myositis-specific antibody context},
author = {Junfeng Su and Yan Du and Chen Zhu and Haodong Zhou and Huyan Wang and Yinjun Du and Qiyuan Wang and Zexin Chen and Hanjun Cao and Man Huang and Jing Xue},
year = {2026},
journal = {Frontiers in Immunology},
doi = {10.3389/fimmu.2026.1960409},
url = {https://doi.org/10.3389/fimmu.2026.1960409}
}RIS
TY - JOUR TI - Anti-Ro52/TRIM21 seropositivity in interstitial lung disease: effect modification by disease subtype and myositis-specific antibody context AU - Junfeng Su AU - Yan Du AU - Chen Zhu AU - Haodong Zhou AU - Huyan Wang AU - Yinjun Du AU - Qiyuan Wang AU - Zexin Chen AU - Hanjun Cao AU - Man Huang AU - Jing Xue PY - 2026 JO - Frontiers in Immunology DO - 10.3389/fimmu.2026.1960409 UR - https://doi.org/10.3389/fimmu.2026.1960409 ER -
APA
Su, J., Du, Y., Zhu, C., Zhou, H., Wang, H., Du, Y., Wang, Q., Chen, Z., Cao, H., Huang, M., & Xue, J. (2026). Anti-Ro52/TRIM21 seropositivity in interstitial lung disease: effect modification by disease subtype and myositis-specific antibody context. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1960409
Source records
- crossref · retrieved 2026-11-10T20:07:15.182Z